Amanote Research
Register
Sign In
Non-Quantifiable Benefit Within the German Amnog System: Factors Contributing to Time Limits Set for Benefit Resolutions and Potential Implications on Price Discounts
Value in Health
- United Kingdom
doi 10.1016/j.jval.2017.08.1680
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2017
Authors
U Beckert
H Vorwerk
J Löpmeier
W Kulp
Publisher
Elsevier BV
Related search
Conditional Resolutions in the Amnog Early Benefit Assessment
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Php237 - Overview of German Amnog Dossiers With Price Analysis Before and After Early Benefit Assessment
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Relationship Between the Price Differences in Orphan Drugs With More Than One Benefit Assessment in Amnog and the Potential Influencing Factors
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn309 - Diversity in Safety Data Analyses in German Amnog Benefit Assessments for Multiple Myeloma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn304 - Appropriate Comparator in German Amnog Benefit Assessments in Melanoma – A Dynamic Situation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn236 - Implications of the Fast Evolving Therapeutic Landscape on Appropriate Comparators in Oncological Amnog Benefit Assessments
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
2.5 Years of Amnog in Germany – An Analysis of Benefit Assessment and Net Price Negotiation Trends
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Inclusion and Consideration of Patient Preferences in Amnog Early Benefit Assessments
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Potential Role of “The Compensating Benefit” in Claiming Non-Inferiority
Trials
Medicine
Pharmacology
